Last checked at 17 May 2021 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
MyHealthChecked Plc
("MyHealthChecked" or the "Company")
Additional Boots agreement for Day 2 & Day 8 testing
Extends supply of COVID-19 testing services for international arrivals to the UK
MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces it has on 16 May signed a second contract with Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group, to supply the MyHealthChecked™ COVID-19 at-home nasal swab kit, laboratory testing service and logistics for day two and day eight ("D2/D8") coronavirus testing for international arrivals.
The contract with Boots for the D2/D8 testing service will run parallel, and be complementary, to the Company's pre-existing agreement, announced on 6 April 2021. MyHealthChecked is currently the only at-home PCR testing kit provider within Boots for General Testing and Fit-to-Fly services, launched on 7 April, and now expands the offering within Boots to include D2/D8 tests that will be available to purchase online, via www.boots.com across the UK, from May 17.
The MyHealthChecked™ COVID-19 testing kit allows customers to take a nasal swab themselves at home and send samples safely and securely via the Royal Mail Tracked 24 service to be tested using established laboratory-based PCR detection methods. D2/D8 testing is undertaken at the Manchester-based laboratories of MyHealthChecked and Yourgene Health plc (AIM: YGEN), with any sequencing required for positive day 2 samples that meet the DHSC sequencing criteria, undertaken at Yourgene Health plc. PCR results are provided to customers within 24-48 hours, via a secure online portal.
The Agreement is on a non-exclusive basis and has an initial term of 12 months from 17 May 2021, with a one-month notice period for termination thereafter.
The contract is expected to have a significant impact on the future performance of the MHC business and whilst volumes are unquantified at this stage, the Board believes it is likely to result in substantial revenue growth in the current financial year ending 31 December 2021.
MyHealthChecked™ also offers the testing kits online via www.myhealthchecked.com.
Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "This is another milestone for MyHealthChecked as currently Boots' only at-home testing kit provider for COVID-19, and we are delighted to build on our pre-existing agreement as the nation begins to open up and we anticipate the possibility of travel with the introduction of the traffic light system. The D2/D8 contract is a testament to the service that MyHealthChecked provides as we pride ourselves on the quality and accuracy of our tests, as well as our operations and customer service.
"We look forward to continuing our partnership with Boots and while it is still in its infancy, we hope to update the market imminently as we deliver on this contract."
MyHealthChecked plc | www.myhealthchecked.com | |
Penny McCormick, Chief Executive Officer | via Walbrook PR | |
Maddy Kennedy, Chief Financial Officer | ||
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 | |
Neil Baldwin | ||
Oberon Capital Ltd (Broker) | Tel: +44 (0)203 179 5344 | |
Mike Seabrook | mikeseabrook@oberoninvestments.com | |
Walbrook PR Ltd (Media & IR) | Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com | |
Paul McManus | Mob: +44(0)7980 541 893 | |
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.
MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.
Glossary:
PCR: polymerase chain reaction